Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate(TM) Trial

por Trotman, Judith, Buske, Christian, Tedeschi, Alessandra, Matous, Jeffrey V., MacDonald, David, Tam, Constantine S., Tournilhac, Olivier, Ma, Shuo, Treon, Steven P., Oriol, Albert, Ping, Jerry, Briso, Eva M., Arango-Hisijara, Israel, Dimopoulos, Meletios A.
Publicado 2021

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

por Buske, Christian, Tedeschi, Alessandra, Trotman, Judith, García-Sanz, Ramón, MacDonald, David, Leblond, Veronique, Mahe, Beatrice, Herbaux, Charles, Matous, Jeffrey V., Tam, Constantine S., Heffner, Leonard T., Varettoni, Marzia, Palomba, M. Lia, Shustik, Chaim, Kastritis, Efstathios, Treon, Steven P., Ping, Jerry, Hauns, Bernhard, Arango-Hisijara, Israel, Dimopoulos, Meletios A.
Publicado 2022